239 related articles for article (PubMed ID: 24777490)
1. Combined use of ¹⁸F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy.
Pengel KE; Koolen BB; Loo CE; Vogel WV; Wesseling J; Lips EH; Rutgers EJ; Valdés Olmos RA; Vrancken Peeters MJ; Rodenhuis S; Gilhuijs KG
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1515-24. PubMed ID: 24777490
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.
Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA
Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441
[TBL] [Abstract][Full Text] [Related]
3. Subtype-Guided
Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
[TBL] [Abstract][Full Text] [Related]
4. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X
Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
[TBL] [Abstract][Full Text] [Related]
5. Early prediction of pathological complete response in luminal B type neoadjuvant chemotherapy-treated breast cancer patients: comparison between interim 18F-FDG PET/CT and MRI.
Pahk K; Kim S; Choe JG
Nucl Med Commun; 2015 Sep; 36(9):887-91. PubMed ID: 25932536
[TBL] [Abstract][Full Text] [Related]
6. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
[TBL] [Abstract][Full Text] [Related]
7. Integrated
Cho N; Im SA; Cheon GJ; Park IA; Lee KH; Kim TY; Kim YS; Kwon BR; Lee JM; Suh HY; Suh KJ
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):328-339. PubMed ID: 29101445
[TBL] [Abstract][Full Text] [Related]
8. Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy.
Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):32-40. PubMed ID: 23929431
[TBL] [Abstract][Full Text] [Related]
9. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
[TBL] [Abstract][Full Text] [Related]
10. The combination of FDG PET and dynamic contrast-enhanced MRI improves the prediction of disease-free survival in patients with advanced breast cancer after the first cycle of neoadjuvant chemotherapy.
Lim I; Noh WC; Park J; Park JA; Kim HA; Kim EK; Park KW; Lee SS; You EY; Kim KM; Byun BH; Kim BI; Choi CW; Lim SM
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1852-60. PubMed ID: 24927797
[TBL] [Abstract][Full Text] [Related]
11. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
[TBL] [Abstract][Full Text] [Related]
12. Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?
Andrade WP; Lima EN; Osório CA; do Socorro Maciel M; Baiocchi G; Bitencourt AG; Fanelli MF; Damascena AS; Soares FA
Eur J Surg Oncol; 2013 Dec; 39(12):1358-63. PubMed ID: 24120422
[TBL] [Abstract][Full Text] [Related]
13. Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.
Schmitz AMT; Teixeira SC; Pengel KE; Loo CE; Vogel WV; Wesseling J; Rutgers EJT; Valdés Olmos RA; Sonke GS; Rodenhuis S; Vrancken Peeters MJTFD; Gilhuijs KGA
PLoS One; 2017; 12(5):e0176782. PubMed ID: 28531188
[TBL] [Abstract][Full Text] [Related]
14. The Role of (18)F-FDG PET/CT and MRI in Assessing Pathological Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Systematic Review and Meta-Analysis.
Liu Q; Wang C; Li P; Liu J; Huang G; Song S
Biomed Res Int; 2016; 2016():3746232. PubMed ID: 26981529
[TBL] [Abstract][Full Text] [Related]
15. Journal Club: Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer.
Miyake KK; Nakamoto Y; Kanao S; Tanaka S; Sugie T; Mikami Y; Toi M; Togashi K
AJR Am J Roentgenol; 2014 Aug; 203(2):272-9. PubMed ID: 25055259
[TBL] [Abstract][Full Text] [Related]
16. The value of pre- and post-neoadjuvant chemotherapy F-18 FDG PET/CT scans in breast cancer: comparison with MRI.
Choi EK; Yoo IR; Kim SH; Park SY; O JH; Kang BJ
Acta Radiol; 2018 Jan; 59(1):41-49. PubMed ID: 28427271
[TBL] [Abstract][Full Text] [Related]
17. Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer.
Kazerouni AS; Peterson LM; Jenkins I; Novakova-Jiresova A; Linden HM; Gralow JR; Hockenbery DM; Mankoff DA; Porter PL; Partridge SC; Specht JM
Breast Cancer Res; 2023 Nov; 25(1):138. PubMed ID: 37946201
[TBL] [Abstract][Full Text] [Related]
18. Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT.
Ueda S; Yoshizawa N; Shigekawa T; Takeuchi H; Ogura H; Osaki A; Saeki T; Ueda Y; Yamane T; Kuji I; Sakahara H
J Nucl Med; 2016 Aug; 57(8):1189-95. PubMed ID: 26940765
[TBL] [Abstract][Full Text] [Related]
19. HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.
Humbert O; Cochet A; Riedinger JM; Berriolo-Riedinger A; Arnould L; Coudert B; Desmoulins I; Toubeau M; Dygai-Cochet I; Guiu S; Coutant C; Fumoleau P; Brunotte F
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1525-33. PubMed ID: 24647576
[TBL] [Abstract][Full Text] [Related]
20. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
Koolen BB; Valdés Olmos RA; Wesseling J; Vogel WV; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Vrancken Peeters MJ
Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]